Can Valeant keep its debt-fueled M&A binge going strong enough? That's the question

Serial dealmaker Valeant ($VRX) seems to have bounced back since its failed bid for Allergan ($AGN) in November. The Canadian pharma has since inked two deals and is rumored to have another one in the works. But its heavy debt load has some questioning whether it can deliver on its goal of becoming one of the world's top 5 drugmakers by 2016. More from FiercePharma

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.